These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid. Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268 [TBL] [Abstract][Full Text] [Related]
5. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II. Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678 [TBL] [Abstract][Full Text] [Related]
6. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Clemente JC; Govindasamy L; Madabushi A; Fisher SZ; Moose RE; Yowell CA; Hidaka K; Kimura T; Hayashi Y; Kiso Y; Agbandje-McKenna M; Dame JB; Dunn BM; McKenna R Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):246-52. PubMed ID: 16510971 [TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654 [TBL] [Abstract][Full Text] [Related]
8. Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite. Westling J; Yowell CA; Majer P; Erickson JW; Dame JB; Dunn BM Exp Parasitol; 1997 Nov; 87(3):185-93. PubMed ID: 9371083 [TBL] [Abstract][Full Text] [Related]
9. Plasmepsins as potential targets for new antimalarial therapy. Ersmark K; Samuelsson B; Hallberg A Med Res Rev; 2006 Sep; 26(5):626-66. PubMed ID: 16838300 [TBL] [Abstract][Full Text] [Related]
10. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825 [TBL] [Abstract][Full Text] [Related]
11. De Novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II. Carcache DA; Hörtner SR; Bertogg A; Binkert C; Bur D; Märki HP; Dorn A; Diederich F Chembiochem; 2002 Nov; 3(11):1137-41. PubMed ID: 12404641 [No Abstract] [Full Text] [Related]
12. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II. Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370 [TBL] [Abstract][Full Text] [Related]
13. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884 [TBL] [Abstract][Full Text] [Related]
14. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum. Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205 [TBL] [Abstract][Full Text] [Related]
15. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor. Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of Plasmepsin II-potential antimalarial agents. Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102 [TBL] [Abstract][Full Text] [Related]
17. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates. Fäh C; Hardegger LA; Baitsch L; Schweizer WB; Meyer S; Bur D; Diederich F Org Biomol Chem; 2009 Oct; 7(19):3947-57. PubMed ID: 19763297 [TBL] [Abstract][Full Text] [Related]
18. Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein. Luksch T; Blum A; Klee N; Diederich WE; Sotriffer CA; Klebe G ChemMedChem; 2010 Mar; 5(3):443-54. PubMed ID: 20112327 [TBL] [Abstract][Full Text] [Related]
19. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids. Degliesposti G; Kasam V; Da Costa A; Kang HK; Kim N; Kim DW; Breton V; Kim D; Rastelli G ChemMedChem; 2009 Jul; 4(7):1164-73. PubMed ID: 19437467 [TBL] [Abstract][Full Text] [Related]
20. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]